NZ512235A - Human hybrid host cell for mammalian gene expression - Google Patents

Human hybrid host cell for mammalian gene expression

Info

Publication number
NZ512235A
NZ512235A NZ512235A NZ51223599A NZ512235A NZ 512235 A NZ512235 A NZ 512235A NZ 512235 A NZ512235 A NZ 512235A NZ 51223599 A NZ51223599 A NZ 51223599A NZ 512235 A NZ512235 A NZ 512235A
Authority
NZ
New Zealand
Prior art keywords
cells
human
recombinant
gene expression
mammalian gene
Prior art date
Application number
NZ512235A
Inventor
Myung-Sam Cho
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Priority to NZ512235A priority Critical patent/NZ512235A/en
Priority claimed from PCT/US1999/029332 external-priority patent/WO2000034462A1/en
Publication of NZ512235A publication Critical patent/NZ512235A/en

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Human/human hybrid cells were made via fusion of human embryonic kidney cells (293S) and modified Burkitt's lymphoma cells (2B8). The fusion cells are useful as host cells for the recombinant expression of mammalian genes. The advantages of using these hybrid clones of human kidney- and B-cells, called HKBs, for mammalian gene expression, include (i) the cells are negative for immunoglobulin expression, (ii) the cells grow easily in plasma protein- free medium (with or without the addition of recombinant insulin) as suspension cultures in a shake flask or in a fermenter (iii) the cells are very susceptible for transfection of DNA, and (iv) the cells secrete high levels of heterologous recombinant proteins, such as recombinant monoclonal antibodies, soluble ICAM-1, rIL-4, and rFVIII
NZ512235A 1999-12-08 1999-12-08 Human hybrid host cell for mammalian gene expression NZ512235A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ512235A NZ512235A (en) 1999-12-08 1999-12-08 Human hybrid host cell for mammalian gene expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ512235A NZ512235A (en) 1999-12-08 1999-12-08 Human hybrid host cell for mammalian gene expression
PCT/US1999/029332 WO2000034462A1 (en) 1998-12-10 1999-12-08 Human hybrid host cell for mammalian gene expression

Publications (1)

Publication Number Publication Date
NZ512235A true NZ512235A (en) 2004-03-26

Family

ID=32041059

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ512235A NZ512235A (en) 1999-12-08 1999-12-08 Human hybrid host cell for mammalian gene expression

Country Status (1)

Country Link
NZ (1) NZ512235A (en)

Similar Documents

Publication Publication Date Title
IL143351A0 (en) Human hybrid host cell for mammalian gene expression
Manuri et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies
Tjian et al. Biological activity of purified simian virus 40 T antigen proteins.
KR20120038531A (en) Method of producing a polypeptide or virus of interest in a continuous cell culture
CA2390281A1 (en) Hematopoietic differentiation of human embryonic stem cells
JPH04228066A (en) Culture cell for expressing exogenote
US4808523A (en) Constitutive production of human IFN-β1 by mammalian cells transformed by the IFN-β1 gene fused to an SV40 early promoter
CN102325881B (en) Expression vector for producing protein derived from foreign gene in large quantity using animal cells, and use thereof
NZ512235A (en) Human hybrid host cell for mammalian gene expression
CN118660958A (en) HEK293 cell strain suitable for serum-free suspension culture and application thereof
AU7710996A (en) Regulated protein expression in stably transfected mammalian cells
EP0235113A2 (en) Immortalization of primary cells
JP2507882B2 (en) Method for producing cell line with good growth independent of external growth factor
Graessmann et al. Fused cells are suited for microinjection
JP2500384B2 (en) Method for producing physiologically active substance
Stein et al. Acidic nuclear protein synthesis in Rous sarcoma virus infected chick embryo fibroblasts
Waldman et al. Transfer of herpes simplex virus thymidine kinase synthesized in bacteria by a high-expression plasmid to tissue culture cells by protoplast fusion
JPH0732705B2 (en) Composition for growing animal cells and method for growing animal cells using the same
AU666800B2 (en) Process for producing exogenous protein
Colman Microinjection and organelle transplantation techniques: Methods and applications: edited by JE Celis, A. Graessmann and A. Loyter, Academic Press, 1986.£ 47/$75.50 (hbk)£ 23/$36.95 (pbk)(xi+ 379 pages) ISBN 0 12 164722 6
Al et al. Optimization of Human Antibody Production by Xenohybridization of EBV-Transformed Cell Lines
Hacker Recombinant Protein Expression in Mammalian Cells
JPH0561907B2 (en)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 08 DEC 2019 BY COMPUTER PACKAGES INC.

Effective date: 20121227

EXPY Patent expired